» Articles » PMID: 1320204

Characterization of a Novel 5-HT4 Receptor Antagonist of the Azabicycloalkyl Benzimidazolone Class: DAU 6285

Overview
Specialty Pharmacology
Date 1992 Mar 1
PMID 1320204
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Three chemical classes of serotonin 5-HT4 receptor agonists have been identified so far: 5-substituted indoles (e.g. 5-HT), benzamides (e.g. renzapride) and benzimidazolones (e.g. BIMU 8). In a search for 5-HT4 receptor antagonists, we have discovered that the benzimidazolone derivative DAU 6285 (for structure see text), is 3-5 times more potent than tropisetron in blocking 5-HT, renzapride and BIMU 8 induced stimulation of adenylate cyclase activity in mouse embryo colliculi neurons. Schild plot analysis yielded Ki values of 220, 181 and 255 nmol/l, respectively. In addition, DAU 6285 showed poor activity as a 5-HT3 receptor ligand with respect to tropisetron, as demonstrated by in vitro binding studies (Ki, 322 vs 2.8 nmol/l) and by its antagonistic activity in the Bezold-Jarisch reflex test (ID50, 231 vs 0.5 micrograms/kg, i.v.). No significant binding (Ki greater than 10 mumol/l) of DAU 6285 to serotonergic 5-HT1A, 5-HT1B, 5-HT1C, 5-HT1D, and 5-HT2 receptors as well as to adrenergic alpha 1, alpha 2, dopaminergic D1, D2 or muscarinic M1-M3 receptor subtypes was found. The data indicate that DAU 6285 has a somewhat higher affinity than tropisetron for 5-HT4 receptors, a property confirmed in functional tests, and much lower affinity than tropisetron for 5-HT3 receptors. The compound represents a new interesting tool for investigating the pharmacological and physiological properties of 5-HT4 receptors.

Citing Articles

Blockade of human and porcine myocardial 5-HT4 receptors by SB 203186.

Parker S, Taylor E, Hamburger S, Vimal M, Kaumann A Naunyn Schmiedebergs Arch Pharmacol. 1995; 353(1):28-35.

PMID: 8750913 DOI: 10.1007/BF00168912.


BIMT 17, a 5-HT2A receptor antagonist and 5-HT1A receptor full agonist in rat cerebral cortex.

Borsini F, Giraldo E, MONFERINI E, Antonini G, Parenti M, BIETTI G Naunyn Schmiedebergs Arch Pharmacol. 1995; 352(3):276-82.

PMID: 8584042 DOI: 10.1007/BF00168557.


The action of SDZ 205,557 at 5-hydroxytryptamine (5-HT3 and 5-HT4) receptors.

Eglen R, Alvarez R, Johnson L, Leung E, Wong E Br J Pharmacol. 1993; 108(2):376-82.

PMID: 8448587 PMC: 1907968. DOI: 10.1111/j.1476-5381.1993.tb12812.x.


Cisapride and a structural analogue, R 76,186, are 5-hydroxytryptamine4 (5-HT4) receptor agonists on the guinea-pig colon ascendens.

Briejer M, Akkermans L, Meulemans A, Lefebvre R, Schuurkes J Naunyn Schmiedebergs Arch Pharmacol. 1993; 347(5):464-70.

PMID: 8321323 DOI: 10.1007/BF00166736.


The guinea-pig distal colon--a sensitive preparation for the investigation of 5-HT4 receptor-mediated contractions.

Wardle K, Sanger G Br J Pharmacol. 1993; 110(4):1593-9.

PMID: 8306106 PMC: 2175885. DOI: 10.1111/j.1476-5381.1993.tb14006.x.


References
1.
Dumuis A, Bouhelal R, Sebben M, Cory R, Bockaert J . A nonclassical 5-hydroxytryptamine receptor positively coupled with adenylate cyclase in the central nervous system. Mol Pharmacol. 1988; 34(6):880-7. View

2.
Dumuis A, Sebben M, Bockaert J . BRL 24924: a potent agonist at a non-classical 5-HT receptor positively coupled with adenylate cyclase in colliculi neurons. Eur J Pharmacol. 1989; 162(2):381-4. DOI: 10.1016/0014-2999(89)90304-x. View

3.
Greengrass P, Bremner R . Binding characteristics of 3H-prazosin to rat brain alpha-adrenergic receptors. Eur J Pharmacol. 1979; 55(3):323-6. DOI: 10.1016/0014-2999(79)90202-4. View

4.
Turconi M, Nicola M, Quintero M, Maiocchi L, Micheletti R, Giraldo E . Synthesis of a new class of 2,3-dihydro-2-oxo-1H-benzimidazole-1-carboxylic acid derivatives as highly potent 5-HT3 receptor antagonists. J Med Chem. 1990; 33(8):2101-8. DOI: 10.1021/jm00170a009. View

5.
Dumuis A, Sebben M, Bockaert J . The gastrointestinal prokinetic benzamide derivatives are agonists at the non-classical 5-HT receptor (5-HT4) positively coupled to adenylate cyclase in neurons. Naunyn Schmiedebergs Arch Pharmacol. 1989; 340(4):403-10. DOI: 10.1007/BF00167041. View